Plus Therapeutics CEO granted options and RSUs

PLUS THERAPEUTICS, INC. reported that Chief Executive Officer Marc H. Hedrick received new equity-based compensation awards.

Rhea-AI Filing Summary

PLUS THERAPEUTICS, INC. reported that Chief Executive Officer Marc H. Hedrick received new equity-based compensation awards. He was granted options to buy 23,834 shares of common stock at an exercise price of $5.76 per share, along with 23,834 restricted stock units, each representing one share.

The restricted stock units vest in 12 equal quarterly installments, beginning on July 1, 2026

Insider Trade Summary

Grant/Award: 47,668 shares

Grant/Award 2 txns

Insider HEDRICK MARC H

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	23,834	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	23,834	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 170,037 contracts (Direct); Stock Option (Right to Buy) — 23,834 contracts (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over twelve quarters in substantially equal 1/12th increments, commencing with 1/12th vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
2. F2. The options vest over four years in substantially equal 1/48th increments on each monthly anniversary of the issuance and vest on a change of control in accordance with the Optionee's employment agreement.

Key Figures

Stock options granted: 23,834 options Option exercise price: $5.76 per share RSUs granted: 23,834 RSUs +4 more

7 metrics

Stock options granted 23,834 options Grant to CEO on May 14, 2026

Option exercise price $5.76 per share Stock Option (Right to Buy) grant

RSUs granted 23,834 RSUs Grant to CEO on May 14, 2026

RSU holdings after grant 170,037 RSUs Total restricted stock units following transaction

RSU vesting schedule 12 quarterly installments 1/12th vesting starting July 1, 2026

Option vesting schedule 48 monthly installments Over four years from grant date

Option expiration May 14, 2036 Expiration date for granted options

Key Terms

Restricted Stock Units, Stock Option (Right to Buy, vest ratably, change of control, +1 more

5 terms

Restricted Stock Units financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy financial

"security_title: "Stock Option (Right to Buy)" with 23,834 underlying shares"

vest ratably financial

"The RSUs awarded vest ratably over twelve quarters in substantially equal 1/12th increments"

change of control financial

"and vest on a change of control in accordance with the Optionee's employment agreement"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

contingent right financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did PLUS THERAPEUTICS (PSTV) grant its CEO?

PLUS THERAPEUTICS granted CEO Marc H. Hedrick 23,834 stock options and 23,834 restricted stock units. Each RSU represents one share of common stock, giving him additional long-term, share-based compensation aligned with the company’s future performance and stock price.

What is the exercise price of the new PLUS THERAPEUTICS CEO stock options?

The new stock options for PLUS THERAPEUTICS’ CEO have an exercise price of $5.76 per share. This means he can buy common shares at $5.76 once the options vest, potentially benefiting if the market price exceeds that level later.

How do the new restricted stock units for PSTV’s CEO vest over time?

The restricted stock units vest ratably over twelve quarters in equal 1/12th increments. Vesting starts on July 1, 2026, and continues quarterly thereafter, encouraging long-term retention and alignment with shareholders over a three-year period.

What is the vesting schedule for PLUS THERAPEUTICS CEO stock options?

The CEO’s stock options vest over four years in 48 equal monthly installments. They also vest upon a change of control under his employment agreement, linking his compensation to both ongoing service and potential strategic corporate events.

How many restricted stock units does the PLUS THERAPEUTICS CEO hold after this grant?

After the new grant, the PLUS THERAPEUTICS CEO holds 170,037 restricted stock units. This figure reflects his increased equity-based position, directly tied to the company’s common stock, and supports long-term incentive alignment with shareholders.

Do the new PLUS THERAPEUTICS CEO awards involve any open-market stock purchases or sales?

No, the filing shows only grant or award acquisitions of options and restricted stock units. There are no open-market purchases or sales, making these routine compensation-related equity awards rather than discretionary trading in PLUS THERAPEUTICS shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HEDRICK MARC H

(Last) (First) (Middle)

C/O PLUS THERAPEUTICS INC.

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON TEXAS 77021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	05/14/2026		A		23,834		(1)	(1)	Common Stock	23,834	$0	170,037	D
Stock Option (Right to Buy)	$5.76	05/14/2026		A		23,834		(2)	05/14/2036	Common Stock	23,834	$0	23,834	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over twelve quarters in substantially equal 1/12th increments, commencing with 1/12th vesting on July 1, 2026 and the remainder vesting quarterly thereafter.

2. The options vest over four years in substantially equal 1/48th increments on each monthly anniversary of the issuance and vest on a change of control in accordance with the Optionee's employment agreement.

	Andrew Sims, as attorney-in-fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)